Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Friday, December 20, 2019
Boston Pharmaceuticals announced the appointment of Joanne Beck, Ph.D., as Chief Operating Officer.
read more
BostonGene, a provider of AI-based molecular and immune profiling solutions, NEC Corporation, a provider of IT, network and AI technologies, and Japan Industrial Partners, a Tokyo-based private equity firm, announced the formation of BostonGene Japan...
read more
Bracco Imaging announced an upgrade of its manufacturing site in Geneva to support clinical-grade GMP manufacturing of its cell therapy-enabling microbubble technology, building on its previously announced Investments in the site since 2019.
read more
Thursday, November 17, 2016
Bracket, a clinical trial technology and specialty services provider, has announced the strategic acquisition of CLINapps Inc., an international software development and consulting firm that offers a comprehensive supply chain management product ...
read more
Tuesday, October 24, 2017
Bracket announced the acquisition of mProve Health, a provider of mobile technologies for life science companies.
read more
Wednesday, November 08, 2017
Bracket announced the addition of Christopher Crucitti, Chief Commercial Officer to its global executive team.
read more
Bracket has announced that James Jay has joined the Company as Senior Vice President, Endpoint Solutions, reporting to Bracket’s Chief Executive Officer, Mike Nolte. In this role, James will lead the Bracket business focused on eCOA, Rater Training, ...
read more
Friday, February 12, 2021
BrainStorm recently concluded a Type C meeting with the FDA to review aspects of the company's planned manufacturing modifications to support the development of a semi-automated commercial manufacturing process for NurOwn.
read more
BrainStorm Cell Therapeutics has contracted with the Connell and O'Reilly Families Cell Manipulation Core Facility at Dana-Farber Cancer Institute as a second U.S. manufacturing site to supply NurOwn.
read more
Tuesday, December 07, 2021
BrainStorm Cell Therapeutics Inc., a developer of cellular therapies for neurodegenerative diseases, and Catalent, a provider of services enabling biopharma, cell, gene and consumer health partners to optimize development, launch, and supply of ...
read more
Tuesday, November 12, 2024
BrainStorm Cell Therapeutics Inc. has entered into a Memorandum of Understanding (MOU) with Pluri Inc. to manufacture NurOwn® for use in BrainStorm's planned Phase 3b trial in amyotrophic lateral sclerosis (ALS).
read more
Wednesday, January 03, 2018
BrainStorm Cell Therapeutics has received GMP approval from the Israel Ministry of Health for its Israeli contract manufacturing facility.
read more
BrainStorm has begun training City of Hope's Center for Biomedicine and Genetics to produce NurOwn adult stem cells for the ALS Phase 3 clinical study.
read more
Thursday, September 27, 2018
Brammer Bio announces that a three-year, $200 million investment program is on track to establish over 30 suites for clinical and commercial viral vector supply for a broad pipeline of advanced gene therapies and gene-modified cell therapies.
read more
Monday, September 18, 2017
Brammer Bio announced completion of its clinical capacity expansion in Alachua, Florida.
read more